Zeinab Zina Pourhashem

Dr. Zeinab Zina Pourhashem

Pasteur Institute of Iran, Tehran, Tehrān, Iran

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MMMasoumeh Mehrpouya
Masoumeh Mehrpouya
ZPZeinab Zina Pourhashem
Zeinab Zina Pourhashem
NYNajmeh Yardehnavi
Najmeh Yardehnavi
MOMorteza Oladnabi
Morteza Oladnabi

2 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
PMPardis Mokhtary
Pardis Mokhtary
ZPZeinab Zina Pourhashem
Zeinab Zina Pourhashem
AMAkram Abouei Mehrizi
Akram Abouei Mehrizi
Claudia SalaClaudia Sala
Claudia Sala
RRRino Rappuoli
Rino Rappuoli
Monoclonal antibodies (mAbs), the new revolutionary class of medications, are fast becoming tools against various diseases thanks to a unique structure and function that allow them to bind highly specific targets or receptors. These specialized proteins can be produced in large quantities via the hybridoma technique introduced in 1975 or by means of modern technologies. Additional methods have been developed to generate mAbs with new biological properties such as humanized, chimeric, or murine. The inclusion of mAbs in therapeutic regimens is a major medical advance and will hopefully lead to significant improvements in infectious disease management. Since the first therapeutic mAb, muromonab-CD3, was approved by the U.S. Food and Drug Administration (FDA) in 1986, the list of approved mAbs and their clinical indications and applications have been proliferating. New technologies have been developed to modify the structure of mAbs, thereby increasing efficacy and improving delivery routes. Gene delivery technologies, such as non-viral synthetic plasmid DNA and messenger RNA vectors (DMabs or mRNA-encoded mAbs), built to express tailored mAb genes, might help overcome some of the challenges of mAb therapy, including production restrictions, cold-chain storage, transportation requirements, and expensive manufacturing and distribution processes. This paper reviews some of the recent developments in mAb discovery against viral infections and illustrates how mAbs can help to combat viral diseases and outbreaks.

1 June 2017 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
ZPZeinab Zina Pourhashem
Zeinab Zina Pourhashem
MMM. Mehrpouya
M. Mehrpouya
NYN. Yardehnavi
N. Yardehnavi
AEA. Eslamparast
A. Eslamparast
FKFatemeh Kazemi-Lomedasht
Fatemeh Kazemi-Lomedasht

24 August 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
LNLeila Nourani
Leila Nourani
MMMasoumeh Ayoub Meigouni
Masoumeh Ayoub Meigouni
SAShima Afzali
Shima Afzali
MZMostafa Zargar
Mostafa Zargar
ZPZeinab Zina Pourhashem
Zeinab Zina Pourhashem
AMAkram Abouie Mehrizi
Akram Abouie Mehrizi

24 January 2024 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
LNLeila Nourani
Leila Nourani
ALAnita Lotfi
Anita Lotfi
HVHediye Vand-Rajabpour
Hediye Vand-Rajabpour
ZPZeinab Zina Pourhashem
Zeinab Zina Pourhashem
FNFahimeh Nemati
Fahimeh Nemati
AMAkram Abouie Mehrizi
Akram Abouie Mehrizi